These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior. Butini S; Gemma S; Campiani G; Franceschini S; Trotta F; Borriello M; Ceres N; Ros S; Coccone SS; Bernetti M; De Angelis M; Brindisi M; Nacci V; Fiorini I; Novellino E; Cagnotto A; Mennini T; Sandager-Nielsen K; Andreasen JT; Scheel-Kruger J; Mikkelsen JD; Fattorusso C J Med Chem; 2009 Jan; 52(1):151-69. PubMed ID: 19072656 [TBL] [Abstract][Full Text] [Related]
29. New antipsychotic agents with serotonin and dopamine antagonist properties based on a pyrrolo[2,1-b][1,3]benzothiazepine structure. Campiani G; Nacci V; Bechelli S; Ciani SM; Garofalo A; Fiorini I; Wikström H; de Boer P; Liao Y; Tepper PG; Cagnotto A; Mennini T J Med Chem; 1998 Sep; 41(20):3763-72. PubMed ID: 9748351 [TBL] [Abstract][Full Text] [Related]
30. Drug effects on pre- and postsynaptic dopamine receptors. Andén NE; Grabowska-Andén M Adv Biochem Psychopharmacol; 1980; 24():57-64. PubMed ID: 6105802 [No Abstract] [Full Text] [Related]
31. [Dependence of the antipsychotic effect of neuroleptics on their dopamine-blocking properties]. Arushanian EB Farmakol Toksikol; 1982; 45(5):118-26. PubMed ID: 6128251 [No Abstract] [Full Text] [Related]
32. Receptor plasticity: biochemical correlates and pharmacological significance. Costa E Adv Biochem Psychopharmacol; 1980; 24():363-77. PubMed ID: 6105787 [No Abstract] [Full Text] [Related]
33. [Some pharmacological aspects of neuroleptics (author's transl)]. Niemegeers CJ Encephale; 1981; 7(3):215-24. PubMed ID: 6116591 [TBL] [Abstract][Full Text] [Related]
34. Drug treatment of schizophrenia. Silverstone T N Z Med J; 1994 Apr; 107(976):145-6. PubMed ID: 7909363 [No Abstract] [Full Text] [Related]
35. Further evidence for the existence of multiple receptors for dopamine in the central nervous system. Iversen LL; Quik M; Emson PC; Dowling JE; Watling KJ Adv Biochem Psychopharmacol; 1980; 21():193-202. PubMed ID: 6103646 [No Abstract] [Full Text] [Related]
36. [Neuroplegics and neuroleptics. Antipsychotics. VI. Butyrophenones (Part I)]. Deligné P; Bunodière M Ann Anesthesiol Fr; 1979; 20(2):147-59. PubMed ID: 38710 [No Abstract] [Full Text] [Related]
37. [Etiology of schizophrenia: neurochemical aspects]. de las Cuevas Castresana C; González de Rivera JL Neurologia; 1994 Feb; 9(2):54-9. PubMed ID: 7515627 [No Abstract] [Full Text] [Related]
38. [How do clozapine and co. work? Pharmacologic mechanisms of atypical neuroleptics]. Müller WE Pharm Unserer Zeit; 2002; 31(6):537-45. PubMed ID: 12481511 [No Abstract] [Full Text] [Related]
39. Supersensitivity of pituitary dopamine receptors involved in the inhibition of prolactin secretion. Annunziato L; Quattrone A; Schettini G; Di Renzo G Adv Biochem Psychopharmacol; 1980; 24():379-85. PubMed ID: 6105788 [No Abstract] [Full Text] [Related]
40. 5-HT3 antagonists and ligands for dopamine D1- and autoreceptors offer new leads for antipsychotic drugs. Abbott A Trends Pharmacol Sci; 1990 Feb; 11(2):49-51. PubMed ID: 1969187 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]